ABSTRACT

Background: Women with ankylosing spondylitis (AS) show a higher rate of cesarean section (CS) compared with healthy women. In this study, we determined the effects of pregnancy and delivery methods on AS worsening by analyzing prescription patterns.

Methods: The subjects were women with AS aged 20–49 years listed in the Korean Health Insurance Review and Assessment Service claims database. Change in treatment was defined as change in prescriptions 1–2 years before delivery or 1 year after delivery. We compared change in prescriptions between AS women with delivery or without delivery (1:1 matched). Moreover, we evaluated change in prescriptions according to delivery method among AS women with delivery.

Results: A total of 6,821 women with AS were included. Women in the delivery group (n = 996) were younger and showed less drug use and lower comorbidity rates than those in the no delivery group. Change in prescriptions did not differ between the delivery and no delivery groups (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.56–1.05). Furthermore, the overall change in prescriptions did not significantly differ between vaginal delivery (VD) and CS (OR, 0.72; 95% CI, 0.45–1.14).

Conclusion: The rate of change in prescriptions was comparable between AS patients with and without delivery. There was no association between the method of delivery and change in prescription. Therefore, pregnancy and VD may not be the factors associated with AS worsening.

Keywords: Ankylosing Spondylitis; Pregnancy; Delivery, Obstetrics

INTRODUCTION

Almost half of the pregnant women experience pain in the lumbar, and/or sacroiliac area, and/or symphysis pubis during pregnancy and following childbirth.1 Ankylosing spondylitis (AS) affects the sacroiliac joints and commonly occurs in the reproductive age; therefore,
many studies have been conducted to evaluate disease activity during and following pregnancy. Reportedly, patients with AS showed higher back pain scores during pregnancy than healthy individuals; however, the pain was less severe in the 1st trimester than before pregnancy in women with AS. Moreover, disease activity was stable during pregnancy, although majority of the women with AS experienced a flare-up during the first 6 months following delivery. In contrast, in a previous study, disease activity was the highest in the 2nd trimester and stable in the year following delivery. Radiologic progression in 4 patients with AS a minimum of 2.5 years following pregnancy and childbirth has been reported. However, there are limited reports on the effects of pregnancy on AS course including non-pregnant AS patients as controls.

The sacroiliac joint is not a part of the pelvic inlet during delivery; however, the rate of cesarean section (CS) is higher in women with AS than in healthy women, which may be related to disease activity. However, the tendency to perform CS in women with inflammatory joint diseases should be considered. Limited studies have focused on whether vaginal delivery (VD) is more likely to affect AS course than CS. Therefore, the present study aimed to examine the effects of pregnancy and delivery methods on AS management using the Korean Health Insurance Review and Assessment Service (HIRA) claims database.

**METHODS**

**Study design and data source**

We conducted a population-based retrospective cohort study using patient records extracted from the HIRA claims database. HIRA includes all health-related information of around 50,000,000 individuals in the entire Korean population covered by the National Health Insurance program.

**Study subjects**

Women aged 20–49 years who were diagnosed with AS (International Classification of Disease and Related Health Problems, 10th revision [ICD-10] M45) and listed in the Korean rare intractable diseases (RID) system between July 1, 2007, and June 30, 2017 were included (Fig. 1). In Korean RID system, AS is diagnosed based on the 1984 Modified New York criteria that comprise the radiographic evidence of sacroiliitis and clinical symptoms. We excluded the women AS without RID codes for diagnostic validation. The subjects were classified into 2 groups: AS patients with delivery or without delivery. Women with AS without delivery records within the study period were classified in the without delivery group. Furthermore, each delivery was categorized by the method of delivery: VD and CS. Women with a history of only one delivery following AS diagnosis were included in the delivery group; this was because a second delivery may require a more conservative management. In addition, the study cohort was restricted to subjects who were diagnosed with AS at least 2 years before delivery, as the prescription of AS medications may be affected by pregnancy. Therefore, 2 time periods—before (~730 to ~365 days) and after (0 to 365 days) delivery—were examined (Fig. 2). The index date was defined as the date of delivery in the delivery group and matched by the age at AS diagnosis and year of AS diagnosis in the without delivery group. Women with AS for whom no information was available on the prescription patterns before and after delivery were excluded.
Women aged 20–49 years old, who had AS diagnostic code (M45) and rare incurable disease exempted calculation code (V140) from July 1, 2007 to June 30, 2017 (n = 6,821)  

996 patients had 1,293 delivery records after the AS diagnosis  
Vaginal delivery (n = 636)  
Cesarean section (n = 657)  

5,825 patients had no delivery record after the AS diagnosis  

Inclusion criteria  
1) Only one delivery record after the AS diagnosis  
2) Delivery date – AS diagnosis date ≥ more than 2 years  
3) Delivery before July 1, 2016: follow-up for 1 year  

418 AS patients without delivery were 1:1 matched (age at AS diagnosis and year of AS diagnosis)  

| Vaginal delivery (n = 207) | Cesarean section (n = 211) |
|---------------------------|---------------------------|

Fig. 1. Selection of study subjects from the Korean Health Insurance Review and Assessment Service database.  
AS = ankylosing spondylitis.

**AS medications and change in prescription**

AS medications included oral non-steroidal anti-inflammatory drugs (NSAIDs), oral corticosteroids, disease modifying anti-rheumatic drugs (DMARDs; including methotrexate and sulfasalazine), and tumor necrosis factor (TNF) inhibitors. The proportion of days covered (PDC) was selected as an index to assess the treatment adherence to NSAIDs and corticosteroids. PDC was defined as the total number of medication-covered days divided by each observation time period (365 days). Adherence was classified as follows: PDC ≥ 0.7 as regular use and PDC < 0.7 as on demand.12

Change in prescription was defined as follows. If a patient 1) initiated the use of new corticosteroids, regular NSAIDs, DMARDs, or TNF inhibitors; 2) received increased mean prescribed daily dose of oral corticosteroids considered equivalent doses; or 3) received increased mean prescribed daily dose of the same generic NSAID or DMARD between the 2 time periods.

| With delivery | Without delivery |
|---------------|-----------------|
| Total 365 days | Total 365 days  |
| Before time period | Preparing and pregnancy period | After time period |
| −730 days | −365 days | 1:1 matched by age at AS diagnosis and year of AS diagnosis |
| Delivery date (index date) | +365 days |
| Before time period | After time period |
| −730 days | Matched index date | +365 days |

Fig. 2. Comparison of change in prescription in AS patients with or without delivery.  
AS = ankylosing spondylitis.
Statistical analyses
All statistical analyses were performed using SAS Enterprise Guide software (version 6.1; SAS Institute, Inc., Cary, NC, USA). Characteristics of AS patient, including age, comorbidities, and medications, were analyzed. Categorical and continuous variables were presented as numbers with percentages and median with interquartile range, respectively. Change in prescription was compared between the AS patient with delivery group and without delivery group using a generalized linear model with a binomial distribution to account for the matched nature of the data. And we also assessed the risk of altering prescribing patterns by delivery method using a generalized linear model with binomial distribution. Multivariable analysis was performed to determine the probability of change in prescription between the 2 groups after adjusting for potential confounders. To assess confounders, univariate analyses were performed independently for the presence of each comorbidity and age group. All variables with P < 0.1 in the univariate analysis were included in multivariable analysis, and backward elimination was performed. Results were reported using adjusted odds ratios (ORs) and their 95% confidence intervals (CIs). P < 0.05 was considered statistically significant.

Ethics statement
This study fulfilled the ethical guidelines of the Declaration of Helsinki. The requirement for informed consent was waived by the Institutional Review Board (IRB) because of the retrospective nature of the study using a database. The waiver from IRB was certified by Asan Medical Center (No. 2017-0431).

RESULTS

Baseline characteristics of AS patients with and without delivery
There were 6,821 fertile women with AS in the Korean cohort, of which 996 had 1,293 delivery records and 5,825 had no delivery records between July 1, 2007, and June 30, 2017 (Fig. 1). AS patients in the delivery group were younger; showed less comorbidities including hypertension, diabetes mellitus, and renal insufficiency at AS diagnosis; and were exposed to fewer AS medications except corticosteroid and DMARDs in a year following AS diagnosis than AS patients in the no delivery group (Table 1). To comparing of altering prescribing patterns between AS patients with and without delivery, 418 women with delivery once after diagnosis of AS were included. Among 5,825 women with AS without delivery code, 418 patients were matched by the age at AS diagnosis and year of AS diagnosis (Fig. 1). After matching, age at AS diagnosis, duration of AS, and comorbidities, except inflammatory bowel disease (IBD), were similar between the 2 groups (Table 1).

Change in prescription in AS patients with and without delivery
AS patients in the delivery group showed lower probability of requiring regular use of new NSAIDs or increased dose of NSAIDs (Table 2). However, overall rate of change in prescription was comparable between the delivery and no delivery groups (OR, 0.74; 95% CI, 0.54–1.01). The result was similar following adjustment for uveitis, IBD and psoriasis (OR, 0.76; 95% CI, 0.56–1.05).

Change in prescription following delivery according to the delivery method
Among the 418 AS patients in the delivery group, 211 patients (50.5%) underwent CS. The frequency of overall change in prescription was similar between CS and VD (OR, 0.68; 95% CI, 0.43–1.06) (Table 3). Similar trends were observed even after adjustments for age and
Table 1. Baseline characteristics of patients with AS with and without delivery

| Characteristics                             | Before matching | After matching | P value* | Standardized differenceb |
|---------------------------------------------|-----------------|----------------|----------|--------------------------|
| Age at AS diagnosis, yr                     |                 |                |          |                          |
| 20–24                                       | 831 (14.3)      | 2 (0.5)        | < 0.001  |                          |
| 25–29                                       | 765 (13.1)      | 21 (1.1)       | < 0.001  |                          |
| 30–34                                       | 986 (16.9)      | 23 (2.3)       | < 0.001  |                          |
| 35–39                                       | 1,172 (20.1)    | 97 (2.2)       | < 0.001  |                          |
| 40–44                                       | 1,082 (18.6)    | 13 (1.1)       | < 0.001  |                          |
| 45–49                                       | 989 (17.0)      | 1 (0.1)        | < 0.001  |                          |
| Duration of AS, yr                          | NE (n = 5,825)  | 4.54 (3.14–6.25)| 0.078   | 0.020                    |

Comorbidityd

| Hypertension                                | 422 (7.2)       | 12 (2.9)       | < 0.001  |                          |
| Diabetes mellitus                           | 350 (6.0)       | 11 (2.6)       | < 0.001  |                          |
| Renal insufficiency                         | 39 (0.7)        | 0 (0.0)        | < 0.001  |                          |
| Uveitis                                     | 880 (15.1)      | 48 (11.5)      | < 0.001  |                          |
| IBD                                         | 618 (10.6)      | 43 (10.3)      | < 0.001  |                          |
| Psoriasis                                   | 137 (2.4)       | 4 (1.0)        | < 0.001  |                          |
| Behçet’s disease                            | 132 (2.3)       | 9 (2.2)        | < 0.001  |                          |

Drug exposuree

| No drug use                                  | 489 (8.4)       | 131 (31.3)     | 0.059    | 0.131                    |
| NSAIDs use                                  | 5,076 (87.7)    | 84 (20.1)      | 0.670    | < 0.030                  |
| Regular use, ≥ 0.7 PDCs                      | 2,455 (42.1)    | 106 (25.4)     | 0.001    | 0.238                    |
| Corticosteroid use, > 14 days               | 1,965 (33.7)    | 91 (21.8)      | 0.866    | < 0.020                  |
| Regular use, ≥ 0.7 PDCs                      | 624 (10.7)      | 26 (6.2)       | 0.414    | < 0.057                  |
| DMARDs use                                  | 3,658 (62.8)    | 124 (29.7)     | 0.013    | 0.173                    |
| TNF inhibitor use                           | 1,162 (19.9)    | 88 (21.1)      | 0.547    | 0.042                    |

Data are presented as number (%).

AS = ankylosing spondylitis, NE = not estimated, IBD = inflammatory bowel disease, NSAIDs = non-steroid anti-inflammatory drugs, PDC = proportion of days covered, DMARDs = disease modifying anti-rheumatic diseases, TNF = tumor necrosis factor.

*P value was estimated by χ² test or Fisher’s exact test; Standardized difference. Standardized difference < 0.1 indicated a negligible difference; ^At AS diagnosis ± 180 days; After 365 days of AS diagnosis.

Table 2. Alteration of prescription patterns after delivery in AS according to delivery after 1:1 matching

| Variables                                  | Without delivery (n = 418) | With delivery (n = 418) | ORa | 95% CI | aORa | 95% CI |
|--------------------------------------------|---------------------------|------------------------|-----|--------|------|--------|
| Overall                                    | 129 (30.9)                | 104 (24.9)             | 0.74| 0.54–1.01| 0.76 | 0.56–1.05|
| Use of new corticosteroid or increase in dose | 39 (9.3)                | 47 (11.2)             | 1.23| 0.79–1.92| 1.30 | 0.83–2.05|
| Regular use of new NSAIDs or increase in dose | 63 (15.1)                | 38 (9.1)              | 0.56| 0.36–0.88| 0.56 | 0.36–0.87|
| Use of new DMARDs or increase in dose      | 59 (14.1)                | 64 (15.3)             | 1.10| 0.76–1.60| 1.10 | 0.75–1.61|
| Use of TNF inhibitors                      | 11 (2.6)                 | 7 (1.7)               | 0.63| 0.24–1.66| 0.65 | 0.24–1.72|

Data are presented as number (%).

AS = ankylosing spondylitis, OR = odds ratio, aOR = adjusted odds ratio, CI = confidence interval, NSAIDs = non-steroid anti-inflammatory drugs, DMARDs = disease modifying anti-rheumatic drugs, TNF = tumor necrosis factor.

*OR of change in prescription patterns compared between 2 groups using a generalized linear model with binomial distribution to account for the matched nature of the data (reference group: without delivery group); Adjusted for the presence of uveitis, inflammatory bowel disease, or psoriasis.

Table 3. Alteration of prescription patterns after delivery in AS according to delivery method

| Variables                                  | Cesarean section (n = 211) | VD (n = 207) | ORa | 95% CI | aORa | 95% CI |
|--------------------------------------------|---------------------------|--------------|-----|--------|------|--------|
| Overall                                    | 60 (28.4)                 | 44 (21.3)    | 0.68| 0.43–1.06| 0.72 | 0.45–1.14|
| Use of new corticosteroid or increase in dose | 22 (10.4)                | 25 (12.1)    | 1.18| 0.64–2.17| 1.23 | 0.66–2.31|
| Regular use of new NSAIDs or increase in dose | 25 (11.8)                | 13 (6.3)     | 0.50| 0.25–1.00| 0.50 | 0.25–1.02|
| Use of new DMARDs or increase in dose      | 37 (17.5)                | 27 (13.0)    | 0.71| 0.41–1.21| 0.73 | 0.42–1.27|
| Use of TNF inhibitors                      | 4 (1.9)                  | 3 (1.4)      | 0.76| 0.37–1.44| 0.89 | 0.19–4.15|

Data are presented as number (%).

AS = ankylosing spondylitis, VD = vaginal delivery, OR = odds ratio, aOR = adjusted odds ratio, CI = confidence interval, NSAIDs = non-steroid anti-inflammatory drugs, DMARDs = disease modifying anti-rheumatic drugs, TNF = tumor necrosis factor.

*OR of change in prescription compared between 2 groups using a generalized linear model with binomial distribution (reference group: cesarean section); Adjusted for the presence of uveitis, inflammatory bowel disease, or psoriasis.
the presence of uveitis, IBD, or psoriasis (OR, 0.72; 95% CI, 0.45–1.14). AS patients with VD showed a lower tendency of requiring the regular use of NSAIDs or increase in the dose of NSAIDs (OR, 0.50; 95% CI, 0.25–1.00), although the difference was not significant following adjustments for age and the presence of uveitis, IBD, or psoriasis.

DISCUSSION

In this population-based retrospective comparative study, the rate of change in prescription was comparable between AS patients with delivery and without delivery. Furthermore, the method of delivery was not associated with increased probability of change in prescription, suggesting negligible effects of VD on AS worsening.

In previous studies, majority of the AS patients experienced aggravated disease activity during pregnancy and flare-up during 6 months following delivery, although this was considered a temporary flare-up associated with the increased physical stress of parturition and care for a newborn. Furthermore, a recent prospective study has reported stable AS activity 1 year following delivery. Similarly, a previous case–control study has shown that the postpartum pain scores in AS returned to the baseline pre-pregnancy levels; therefore, pregnancy did not aggravate AS activity. In the present study, the 1:1 ratio with the control group matched in terms of age at and year of AS diagnosis was used, and change in AS management was assessed. According to the recommendations of European League Against Rheumatism-Assessment of Spondyloarthritis International Society (EULAR-ASAS), NSAIDs are recommended as the first-line treatment for AS patients with pain or stiffness and DMARDs, including sulfasalazine or methotrexate, are recommended for patients with peripheral arthritis. Although long-term corticosteroids use is discouraged, short-term corticosteroid use is effective in patients with axial symptoms. The use of TNF inhibitors should be considered in patients with persistently high disease activity despite conventional treatment. Based on this recommendation, using new NSAIDs, DMARDs, corticosteroids, and TNF inhibitors or increasing the doses of NSAIDs, DMARDs, or corticosteroids may reflect a worsening disease. Change in prescription was noted in 24.9% (104/418) of the patients 1 year after delivery, and similar rate was noted in the no delivery group (30.9%; 129/418). To the best of our knowledge, this is the first study comparing change in prescription between AS patients with and without delivery, and our result provide evidence that may offer assurance to women with AS planning pregnancy.

Previous studies have shown that women with AS show a higher risk of CS than healthy women. Furthermore, the rate of elective CS was higher than that of emergent CS in women with AS, although the indications for CS were comparable. In the present study, the rate of CS (50.5%) in women with AS was higher than that in the general Korean women population. Although, we could not distinguish elective CS from emergent based on the HIRA database, concerns regarding the possibility of disease aggravation following delivery should be considered among women with AS when selecting the delivery method. In the present study, VD was not associated with increased probability of change in prescription. The sacroiliac joint is not a part of the pelvic inlet and is not mechanically inherent during delivery, which may explain why VD was not associated with change in AS management. Indeed, according to the core set of recommendations for patients with AS, CS is not required in women with sacroiliac joint fusion or hip joint replacement. Based on this result, it is recommended that pregnant women with AS opt for VD if they are concerned about disease course without any other indication for CS.
The present study has some limitations. First, change in prescription could not directly reflect a worsened disease. Second, change in prescription was compared at only 2 time periods (1–2 years before delivery and 1 year after delivery). The period 2 years before delivery was selected to avoid the bias of change in medications for planning a pregnancy; however, the period 1 year after delivery may be affected by confounders including breast feeding and may be relatively short to evaluate the effects of pregnancy and delivery. Third, although we conducted study using a nationwide database, few events were detected, and there were no significant differences in the evaluated parameters as the power of analysis was considerably low. Finally, the accessibility of medical services during prenatal periods differs with regions; thus, the place of residence could be a confounding factor for change in prescription. Despite these limitations, this is the first study to compare change in AS treatment according to pregnancy and delivery methods.

In conclusion, the rate of change in prescription was comparable in AS patients with delivery and without delivery, and the method of delivery was not associated with change in prescription. Thus, pregnancy and delivery method do not contribute to change in treatment after delivery in women with AS, and pregnancy and VD may be encouraged in women with AS who are concerned of AS worsening.

ACKNOWLEDGMENTS

We thank the Korean Health Insurance Review and Assessment Service and the National Health Insurance Service for providing the insurance claims data. The authors would like to thank Enago (http://www.enago.co.kr) for the English language review.

REFERENCES

1. Bergström C, Persson M, Mogren I. Pregnancy-related low back pain and pelvic girdle pain approximately 14 months after pregnancy - pain status, self-rated health and family situation. BMC Pregnancy Childbirth 2014;14:48. PUBMED | CROSSREF
2. Lui NL, Haroon N, Carty A, Shen H, Cook RJ, Shanmugarajah S, et al. Effect of pregnancy on ankylosing spondylitis: a case-control study. J Rheumatol 2011;38(11):2442-4. PUBMED | CROSSREF
3. Ostensen M. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. Am J Reprod Immunol 1992;28(3-4):235-7. PUBMED | CROSSREF
4. Ostensen M, Husby G. Ankylosing spondylitis and pregnancy. Rheum Dis Clin North Am 1989;15(2):241-54. PUBMED
5. Ostensen M, Romberg O, Husby G. Ankylosing spondylitis and motherhood. Arthritis Rheum 1982;25(2):140-3. PUBMED | CROSSREF
6. Ursin K, Lydersen S, Skomsvoll JF, Wallenius M. Disease activity during and after pregnancy in women with axial spondyloarthritis: a prospective multicentre study. Rheumatology (Oxford) 2018;57(6):1064-71. PUBMED | CROSSREF
7. Jakobsson GL, Stephansson O, Askling J, Jacobsson LT. Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis 2016;75(10):1838-42. PUBMED | CROSSREF
8. Ostensen M, Ostensen H. Ankylosing spondylitis--the female aspect. J Rheumatol 1998.25(1):120-4. PUBMED
9. Dunkin MA. Rheumatoid arthritis and pregnancy. https://www.arthritis.org/living-with-arthritis/life-stages/pregnancy-family/pregnancy-and-rheumatoid-arthritis.php. Accessed June 3, 2019.
10. Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. *J Korean Med Sci* 2017;32(5):718-28.

11. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27(4):361-8.

12. Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, et al. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. *Arthritis Care Res (Hoboken)* 2015;67(5):624-32.

13. Østensen M, Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. *Arthritis Rheum* 1983;26(9):1155-9.

14. Østensen M, Fuhrer L, Mathieu R, Seitz M, Villiger PM. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. *Ann Rheum Dis* 2004;63(10):1212-7.

15. Timur H, Tokmak A, Türkmen GG, Ali İnal H, Uygur D, Danışman N. Pregnancy outcome in patients with ankylosing spondylitis. *J Matern Fetal Neonatal Med* 2016;29(15):2470-4.

16. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis* 2017;76(6):978-91.

17. Chung SH, Seol HJ, Choi YS, Oh SY, Kim A, Bae CW. Changes in the cesarean section rate in Korea (1982–2012) and a review of the associated factors. *J Korean Med Sci* 2014;29(10):1341-52.

18. Feldtkeller E, Lind-Albrecht G, Rudwaleit M. Core set of recommendations for patients with ankylosing spondylitis concerning behaviour and environmental adaptations. *Rheumatol Int* 2013;33(9):2343-9.

19. Kwak MY, Lee SM, Lee TH, Eun SJ, Lee JY, Kim Y. Accessibility of prenatal care can affect inequitable health outcomes of pregnant women living in obstetric care underserved areas: a nationwide Population-based study. *J Korean Med Sci* 2019;34(1):e8.